Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study

Fineline Cube Mar 29, 2023

China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced...

Company Deals

Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment

Fineline Cube Mar 29, 2023

Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based...

Company R&D

AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030

Fineline Cube Mar 29, 2023

At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the...

Company

Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth

Fineline Cube Mar 29, 2023

Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the...

Company Drug

CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments

Fineline Cube Mar 29, 2023

The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...

Company Drug

Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment

Fineline Cube Mar 28, 2023

Brii Biosciences has announced a strategic decision to end the manufacturing and further development of...

Company Deals

Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening

Fineline Cube Mar 28, 2023

Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...

Company

PharmaBlock Expands US Presence with New R&D Facility in West Chester

Fineline Cube Mar 28, 2023

PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...

Company Drug

CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent

Fineline Cube Mar 28, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...

Policy / Regulatory

NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations

Fineline Cube Mar 28, 2023

The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...

Company Deals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

Fineline Cube Mar 28, 2023

Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...

Company Medical Device

Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA

Fineline Cube Mar 28, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008

Fineline Cube Mar 28, 2023

Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...

Company Drug

Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review

Fineline Cube Mar 28, 2023

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...

Company

Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs

Fineline Cube Mar 28, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....

Policy / Regulatory

National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety

Fineline Cube Mar 28, 2023

The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...

Policy / Regulatory

China’s New Internet Advertising Regulations Impact Pharmaceutical Sector

Fineline Cube Mar 28, 2023

The State Administration for Market Regulation has released the latest version of the “Measures for...

Company

Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report

Fineline Cube Mar 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China

Fineline Cube Mar 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...

Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Mar 27, 2023

US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...

Posts pagination

1 … 485 486 487 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.